We’re taking a comprehensive approach to ensuring sickle cell disease (SCD) patients in sub-Saharan Africa, regardless of income, have access to our portfolio of medicines. Press play to learn more.
SWAY was a multi-country, cross-sectional survey developed by international SCD experts, patient advocacy groups, and Novartis to assess the impact of SCD on the daily lives of patients.
In sickle cell disease, vaso-occlusion and VOCs can lead to many complications.
VOC = vaso-occlusive crisis.
See how sickle cell disease and vaso-occlusive crises impact the body. Press play to learn more.
Crizanlizumab, a first-in-class humanized, anti-P-selectin monoclonal antibody. See the role of P-selectin in the pathophysiology of sickle cell disease and how crizanlizumab impacts the process.
From utilizing CRISPR genome editing technology to collaborating on drug discovery with the Bill & Melinda Gates Foundation, Novartis continues to search for ways to improve the lives of sickle cell patients across the globe.
Study of Two Doses of Crizanlizumab Versus Placebo in Adolescent and Adult Sickle Cell Disease Patients
A Study to Evaluate the Safety and Efficacy of Crizanlizumab in Sickle Cell Disease Related Priapism
Study Exploring the Effect of Crizanlizumab on Kidney Function in Patients With Chronic Kidney Disease Caused by Sickle Cell Disease
P-selectin–targeting monoclonal antibody
